معرفی
Mats Jerkeman is a Professor and Senior Consultant at Lund University, where he serves as Head of Department and Principal Investigator at Lund University Cancer Centre (LUCC). His research focuses on malignant lymphomas, with a tripartite strategy: clinical trial development, clinical epidemiology using the Swedish Lymphoma Registry, and translational research identifying treatment-predictive biomarkers.
- Key Affiliations: Lund University, LUCC, Nordic Lymphoma Group
- Research Pillars: Clinical Trials, Lymphoma Epidemiology, Translational Biomarker Discovery
Dr. Jerkeman's work extends to optimizing treatment protocols through registry-data hybrid trials and advancing CD163+ macrophage-targeted therapies in mantle cell lymphoma. He has spearheaded multinational analyses on ibrutinib outcomes and contributed to ESMO Clinical Practice Guidelines for lymphomas. His team's recent focus includes ctDNA profiling and circSCORE validation for relapsed/refractory cases.
As Head of Department, he has organized major conferences like the 7th Swedish Cancer Research Meeting and LUCC LITENING Immunotherapy Symposium, while supervising projects such as the MCL7 VALERIA trial and Ig-deficiency in rituximab-treated patients. His expertise directly contributes to UN Sustainable Development Goal #3 (Good Health and Well-Being) through cancer research advancements.
